Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-117 · 4 trials · 4 indications
Estimated glomerular filtration rate
AE : Adverse Events, SAE: Serious Adverse Events
| Arm | Type | Description |
|---|---|---|
| ARGX-117 | EXPERIMENTAL | Patients receiving ARGX-117 intravenous infusions |
| Placebo | PLACEBO_COMPARATOR | Patients receiving placebo intravenous infusions |
| ARGX-117 IV | EXPERIMENTAL | Subjects receiving ARGX-117 IV |
| Placebo IV | PLACEBO_COMPARATOR | Subjects receiving placebo IV |
| ARGX-117 PH20 SC | EXPERIMENTAL | Subjects receiving ARGX-117 PH20 SC |
| Placebo PH20 SC | PLACEBO_COMPARATOR | Subjects receiving placebo PH20 SC |
| ARGX-117 + rHuPH20 | EXPERIMENTAL | Subjects receiving ARGX-117 + rHuPH20 |
| Placebo + rHuPH20 | PLACEBO_COMPARATOR | Subjects receiving placebo + rHuPH20 |
| Name | Type | Description |
|---|---|---|
| ARGX-117 | BIOLOGICAL | Intravenous administration of ARGX-117 |
| Placebo | OTHER | Intravenous administration of placebo |
| ARGX-117 + rHuPH20 | BIOLOGICAL | Subjects treated with ARGX-117 + rHuPH20 |
| placebo + rHuPH20 | OTHER | Subjects treated with placebo + rHuPH20 |
| ARGX-117 PH20 SC | BIOLOGICAL | Subjects treated with ARGX-117 PH20 SC |
| Placebo PH20 SC | OTHER | Subjects treated with placebo PH20 SC |
Inclusion Criteria: * Is at least the local legal age of consent for clinical studies and at least aged 18 years and less than 70 years * Agree to use contraceptive measures consistent with local regulations * Are diagnosed with ESRD and have been stable on chronic dialysis for at least 3 months * ...
ARGX-117 is an investigational monoclonal antibody being studied for multifocal motor neuropathy (MMN) and delayed graft function in deceased donor kidney transplant recipients. It has also been evaluated in healthy volunteers. The drug is in Phase 2 clinical development for these conditions.
ARGX-117 targets complement protein C2, which is part of the complement system. By targeting C2, the drug is designed to modulate complement pathway activity. This mechanism is being investigated in conditions like multifocal motor neuropathy and delayed graft function.
ARGX-117 is being developed by argenx SE, a biopharmaceutical company traded on the NASDAQ under the ticker ARGX. The company is conducting clinical trials to evaluate the safety, efficacy, and pharmacokinetics of ARGX-117 in multiple patient populations.
ARGX-117 is in Phase 2 clinical development. It has completed a Phase 1 study in healthy volunteers and is being evaluated in Phase 2 trials for multifocal motor neuropathy and delayed graft function. The drug is investigational and has not been approved by regulatory authorities.
ARGX-117 is being studied in several clinical trials. NCT04532125 is a completed Phase 1 study in healthy volunteers. NCT05225675 is a completed Phase 2 trial in multifocal motor neuropathy. NCT05405361 is an active Phase 2 long-term extension study in MMN, and NCT05907096 is an active Phase 2 trial in delayed graft function.
ARGX-117 is the sole name provided for this investigational drug. It is a monoclonal antibody targeting complement protein C2, developed by argenx SE. No alternative names or brand names have been associated with this asset in the available clinical trial information.